Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen
- 1 October 2010
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 15 (7) , 993-1002
Abstract
Background: Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed. Methods: We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load + T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV. Conclusions: An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.Keywords
This publication has 19 references indexed in Scilit:
- Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsClinical Infectious Diseases, 2010
- Abacavir and cardiovascular riskCurrent Opinion in Infectious Diseases, 2010
- New therapeutic strategies for raltegravirJournal of Antimicrobial Chemotherapy, 2009
- Efficacy and Safety of an NRTI-Sparing Dual Regimen of Raltegravir and Ritonavir-Boosted Protease Inhibitor in a Triple Antiretroviral Class-Experienced PopulationHIV Research & Clinical Practice, 2009
- Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patientsAIDS, 2009
- Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patientsAIDS, 2008
- A 96‐Week Comparison of Lopinavir‐Ritonavir Combination Therapy Followed by Lopinavir‐Ritonavir Monotherapy versus Efavirenz Combination TherapyThe Journal of Infectious Diseases, 2008
- Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trialJournal of Antimicrobial Chemotherapy, 2007
- Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week ResultsClinical Infectious Diseases, 2007
- 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failuresAIDS, 2006